Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

Primary care physicians (PCPs) play a key role in treating young patients as they progress through the "atopic march" from atopic dermatitis through food allergy, asthma, and allergic rhinitis.

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Medscape Medical News, October 16, 2024 PCPs Are Key to Halting Atopic March Families rely on PCPs to manage, or ideally prevent, the progression of allergic disorders in young patients.

Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or ...

Atopic dermatitis (eczema) is diagnosed by a healthcare provider based on a combination of a person's symptoms and medical history, as well as a physical exam. Laboratory tests are sometimes performed ...

Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has backed a winner. The company has claimed across-the ...

Organon (NYSE:OGN) projected a roughly 75 basis-point headwind to the company’s 2025 EBITDA margin on Tuesday after the FDA delayed a potential label expansion for its skin disorder therapy VTAMA ...

In children, allergic diseases often start with eczema and food hypersensitivity, followed by asthma and hay fever. The development of allergic diseases is called the "atopic march" and is seen to ...

Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease that occurs most frequently in children but also affects many adults. The Academy is publishing a series of updates to the AD ...